Ascendis Pharma Statistics
Total Valuation
Ascendis Pharma has a market cap or net worth of $15.05 billion. The enterprise value is $14.64 billion.
| Market Cap | 15.05B |
| Enterprise Value | 14.64B |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, after market close.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Ascendis Pharma has 65.67 million shares outstanding. The number of shares has increased by 6.52% in one year.
| Current Share Class | 65.67M |
| Shares Outstanding | 65.67M |
| Shares Change (YoY) | +6.52% |
| Shares Change (QoQ) | +5.89% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 80.19% |
| Float | 65.64M |
Valuation Ratios
The trailing PE ratio is 17.13 and the forward PE ratio is 32.93.
| PE Ratio | 17.13 |
| Forward PE | 32.93 |
| PS Ratio | 12.59 |
| Forward PS | 8.77 |
| PB Ratio | 9.17 |
| P/TBV Ratio | 9.20 |
| P/FCF Ratio | 40.10 |
| P/OCF Ratio | 38.45 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 48.64, with an EV/FCF ratio of 39.00.
| EV / Earnings | 17.28 |
| EV / Sales | 12.24 |
| EV / EBITDA | 48.64 |
| EV / EBIT | 49.54 |
| EV / FCF | 39.00 |
Financial Position
The company has a current ratio of 2.99, with a Debt / Equity ratio of 0.31.
| Current Ratio | 2.99 |
| Quick Ratio | 2.23 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 1.63 |
| Debt / FCF | 1.37 |
| Interest Coverage | 2.01 |
Financial Efficiency
Return on equity (ROE) is 118.78% and return on invested capital (ROIC) is 12.98%.
| Return on Equity (ROE) | 118.78% |
| Return on Assets (ROA) | 9.58% |
| Return on Invested Capital (ROIC) | 12.98% |
| Return on Capital Employed (ROCE) | 14.20% |
| Weighted Average Cost of Capital (WACC) | 7.43% |
| Revenue Per Employee | $1.01M |
| Profits Per Employee | $712,727 |
| Employee Count | 1,189 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 0.30 |
Taxes
| Income Tax | -735.66M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.49 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 246.09 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 42.85 |
| Average Volume (20 Days) | 982,558 |
Short Selling Information
The latest short interest is 3.96 million, so 7.13% of the outstanding shares have been sold short.
| Short Interest | 3.96M |
| Short Previous Month | 4.20M |
| Short % of Shares Out | 7.13% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.31 |
Income Statement
In the last 12 months, Ascendis Pharma had revenue of $1.20 billion and earned $847.43 million in profits. Earnings per share was $13.38.
| Revenue | 1.20B |
| Gross Profit | 1.09B |
| Operating Income | 295.51M |
| Pretax Income | 111.78M |
| Net Income | 847.43M |
| EBITDA | 300.99M |
| EBIT | 295.51M |
| Earnings Per Share (EPS) | $13.38 |
Balance Sheet
The company has $927.98 million in cash and $514.19 million in debt, with a net cash position of $413.78 million or $6.30 per share.
| Cash & Cash Equivalents | 927.98M |
| Total Debt | 514.19M |
| Net Cash | 413.78M |
| Net Cash Per Share | $6.30 |
| Equity (Book Value) | 1.64B |
| Book Value Per Share | 24.99 |
| Working Capital | 1.06B |
Cash Flow
In the last 12 months, operating cash flow was $391.56 million and capital expenditures -$16.12 million, giving a free cash flow of $375.43 million.
| Operating Cash Flow | 391.56M |
| Capital Expenditures | -16.12M |
| Depreciation & Amortization | 5.37M |
| Net Borrowing | -33.75M |
| Free Cash Flow | 375.43M |
| FCF Per Share | $5.72 |
Margins
Gross margin is 91.30%, with operating and profit margins of 24.70% and 70.84%.
| Gross Margin | 91.30% |
| Operating Margin | 24.70% |
| Pretax Margin | 9.34% |
| Profit Margin | 70.84% |
| EBITDA Margin | 25.16% |
| EBIT Margin | 24.70% |
| FCF Margin | 32.01% |
Dividends & Yields
Ascendis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -6.52% |
| Shareholder Yield | -6.52% |
| Earnings Yield | 5.63% |
| FCF Yield | 2.49% |
Analyst Forecast
The average price target for Ascendis Pharma is $307.08, which is 33.96% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $307.08 |
| Price Target Difference | 33.96% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (3Y) | 52.23% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ascendis Pharma has an Altman Z-Score of 8.97 and a Piotroski F-Score of 7.
| Altman Z-Score | 8.97 |
| Piotroski F-Score | 7 |